Lantern Pharma CEO Discusses The Addition Of Its New ADC Program And The Resurgence Of ADC Therapy For Cancer Treatment 3 years ago [#item_full_content] ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2019 Operating ResultsDateJuly 18, 2019In relation toSimilar postImmunoGen Announces Conference Call to Discuss Its Third Quarter 2019 Operating ResultsDateOctober 18, 2019In relation toSimilar postAntibody Drug Conjugates Market, 2030 – Type of Payload, Type of Linker, Target Indications, Target Antigens, Technology Providers, Key Geographies – ResearchAndMarkets.comDateNovember 5, 2019In relation toSimilar post
